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Abstract
Importance—Approximately 4–5% of breast cancer survivors will develop a new ipsilateral or 
contralateral cancer (“in-breast event”) over the 5 years following diagnosis, and annual 
surveillance mammography is recommended for those with residual breast tissue. The risk for 
such in-breast events persists over time, though increasing age at cancer diagnosis and treatment 
with hormonal therapy are associated with lower risk, and most older breast cancer survivors will 
ultimately die from non-breast cancer related causes. Specific guidelines for surveillance strategies 
in older patients are limited. Prospective data on the benefits and harms of surveillance 
mammography in this population are lacking, and most of the evidence is derived from 
observational, retrospective data, often in the general population.
Observations—We review the current recommendations for breast cancer screening and 
surveillance for older patients, the current evidence for ipsilateral and contralateral breast cancer 
risks in older breast cancer survivors, and suggested approaches for discussions about surveillance 
mammography with older patients. We recommend individualized decision-making for 
surveillance breast imaging in older breast cancer survivors, with consideration of the following 
strategy for women age ≥70: one-time imaging 6–12 months after completion of local therapy 
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followed by annual or biennial surveillance mammography for healthy women and cessation of 
mammography in patients whose life expectancy is <5–10 years, regardless of age. Decisions on 
mammographic surveillance should also incorporate whether hormonal therapy is being 
administered, whether one’s anticipated life expectancy is extraordinary, and whether one’s 
individual risk for in-breast events is higher (or lower) than for average-risk breast cancer 
survivors.
Conclusions and Relevance—We propose re-framing discussions around surveillance 
mammography in older breast cancer survivors and to consider cessation, while taking into 
account life expectancy, the estimated risk for subsequent in-breast events and patient preferences.
Introduction
Breast cancer is a disease of aging. Approximately 40,000 women aged 70–79 and 30,000 
women age ≥80 develop breast cancer annually,1,2 and for those age ≥70, the probability of 
developing breast cancer over the next ten years is 1 in 27 (3.7%).2 Although most breast 
cancers in older women are lower-risk and most older breast cancer patients die of other 
causes,3–5 nearly 19,000 breast cancer deaths occur annually in women age ≥70, accounting 
for 47% of all breast cancer deaths in the U.S.6
Past recommendations for annual screening mammography for women age ≥40 have been 
recently challenged by new and significantly revised national guidelines. The American 
Cancer Society (ACS)7 and the United States Preventative Services Task Force (USPSTF)8 
now recommend biennial screening for average-risk women and encourage individualized 
shared decisions about when to begin screening and at what frequency. Clear guidance is 
lacking regarding decisions about screening for older women, largely because of a lack of 
available prospective data on how mammography impacts breast cancer mortality in this 
population.
Even fewer data are available to guide recommendations on surveillance mammography for 
older breast cancer survivors. This is particularly problematic for clinicians caring for an 
aging U.S. population with increasing numbers of older patients who will develop cancer.9 
Once a breast cancer is diagnosed, current guidelines encourage annual surveillance 
mammography for all patients with residual breast tissue and do not specifically tailor 
follow-up strategies. Further, studies have consistently shown that the risk of second breast 
cancer events in survivors does not plateau with time, suggesting that there may be 
continued benefit of mammography indefinitely.10,11 Explicit guidance on how to approach 
surveillance in older or frail breast cancer survivors is lacking. Further, the limited data 
regarding surveillance in older cancer survivors across all cancers is now widely recognized 
as a significant research gap and priority.12
We review existing guidelines for breast cancer screening and surveillance for older women, 
the risks for subsequent in-breast events in older breast cancer survivors, and the expected 
benefits and risks of surveillance breast imaging. In this context, we propose potential 
alternative surveillance strategies for older breast cancer survivors.
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Current Recommendations for Mammographic Screening in Older Women
The primary benefit of screening is a reduction in breast cancer mortality, estimated to be 
14–33% for women aged 50–74, with minimal data available to guide screening in those age 
≥75 because of a lack of inclusion of these women in prospective, breast cancer screening 
trials.7,8,13–15 The most recent screening recommendations from national and international 
societies (Table 1) have aimed to better reflect and balance the potential benefits and harms 
of screening mammography with maximization of improvements in breast cancer mortality 
and minimization of the risks of screening.16,17 These recommendations recognize the value 
of screening programs but also the importance of a personalized approach that incorporates a 
woman’s cancer risk as well as her preferences regarding the relative benefits and harms of 
screening.17,18
The benefits of mammography are strongly correlated with age. Women who benefit the 
most from a breast cancer mortality perspective are those aged 50–6915 (Relative Risk [RR] 
for death for women aged 50–59 receiving mammography vs. not = 0.86 [95% CI=0.68–
0.97] and RR for women aged 60–69 receiving mammography vs. not =0.67 [95% CI=0.54–
0.83]).15 For women aged 70–74, data are limited, although a recent meta-analysis reported 
a RR=0.80 (95% CI−0.51–1.28) for breast cancer mortality with mammography.15 The 
harms of screening mammography have also been well described and include false positives 
and unnecessary biopsies, distress regarding additional testing, and over-diagnosis.19–23 It is 
at the extremes of age where the harms may be greatest and benefits are least (i.e. youngest 
patients) or for whom the balance of risk-to-benefit is unknown (i.e. older patients), and 
where the guidelines provide limited direction for providers and patients.
Current breast cancer screening guidelines in older women are conflicting. The USPSTF 
states that for women age ≥75, “current evidence is insufficient to assess the balance of 
benefits and harms of screening.”8 This lack of clarity is largely based on the limited 
numbers of women over age 70 in screening studies,24 and the non-significant reduction in 
breast cancer mortality with mammography among these women. No randomized control 
trials in screening populations have included women age ≥75. Current guidelines from the 
National Comprehensive Cancer Network (NCCN)25 recommend annual screening 
mammography for most women, specifically stating that “with the high incidence of breast 
cancer in the elderly population, the same screening guidelines used for women who are age 
≥40 are recommended. Clinicians should always use judgment when applying screening 
guidelines.”25 The evidence for screening mammography in older women was thoughtfully 
reviewed by Walter and Schonberg,26 who concluded: “For women with less than a 5–10 
year life expectancy, recommendations to stop screening mammography should be framed 
around increased harms and the need to refocus health promotion on interventions likely to 
be beneficial over a shorter timeframe. For women with life expectancy of >5–10 yrs, the 
decision about whether potential benefits of screening outweigh harms is a value judgment 
that requires a realistic understanding of screening outcomes.26 The newest guidelines from 
the ACS7 have provided similar guidance regarding cessation of screening, stating: “women 
aged ≥55 should have biennial screening and women should continue screening 
mammography as long as their overall health is good and they have a life expectancy of 10 
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years or longer.”16 It is not clear if any of these guidelines have impacted the rates of 
mammography in the oldest patients.
Current Recommendations for Surveillance Mammography in Older Breast 
Cancer Survivors
Recommendations for surveillance mammography in breast cancer survivors from the ACS 
and American Society of Clinical Oncology (ASCO) recommend annual mammography in 
all breast cancer survivors with residual breast tissue.27 For older patients, these 
recommendations lack information regarding the balance of harms and benefits of 
surveillance mammography; the number of false positives is less well defined than in 
screening populations and may be underemphasized in practice due to concerns for a higher 
risk of second breast cancers and local recurrences. Recently revised ‘Older Adult 
Oncology’ NCCN guidelines address surveillance in older breast cancer survivors, noting 
that decisions should be based primarily on patient preference and life expectancy, 
promoting routine calculation of estimated life expectancy to inform decisions (Table 
2).28,29
Not surprisingly, there is variability in the rates of surveillance mammograms in older breast 
cancer survivors. Studies in Medicare beneficiaries indicate that 77–91% of breast cancer 
survivors undergo mammography after diagnosis and that the rates of mammography wane 
over time and with increasing age.30,31 Having regular follow-up with providers is also 
associated with higher rates of surveillance mammography.31
Risk of In-Breast Events in Older Breast Cancer Survivors
The goal of mammography in the surveillance setting is to detect new, early-stage or 
recurrent cancers that would affect a woman’s longevity. In order to calculate the benefits of 
surveillance mammography in older patients, it is useful to first consider the risks for in-
breast events (ipsilateral and contralateral) in older breast cancer survivors with residual 
breast tissue.
Risk for Ipsilateral Recurrence in Breast Cancer Survivors Who Undergo Breast 
Conservation
Although the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)32 reported an 
overall risk for distant or local recurrence for patients treated with breast conserving surgery 
(BCS) only at 10 years of 35.0% compared with 19.7% in those receiving BCS with 
radiation, recurrences decreased with increasing age and with estrogen receptor (ER)-
positive disease. In women aged 60–69 and ≥70, the 10-year risk of locoregional or distant 
recurrence for those receiving radiation was 14.2% and 8.8%, respectively (vs. 36.1% for 
women age ≤40).32 Rates of recurrence in the EBCTCG analysis were further lowered by 
the use of endocrine therapy and chemotherapy, although interpretations are limited because 
local and metastatic recurrences were reported together.32
For women with ER-positive disease taking tamoxifen in the EBCTCG analysis, the 10-year 
risk of locoregional or distant recurrence was 8.7% in radiation-treated patients and 22.0% 
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in BCS-only treated patients, whereas rates of recurrence with and without radiation for 
those with ‘ER-poor’ disease were 28.9% and 43.8%, suggesting the importance of tumor 
biology when calculating ipsilateral recurrence risk.32 Further, in a single institution study, 
at 6 years of follow-up after an initial breast cancer, 7% of women with triple negative/basal 
tumors developed an ipsilateral recurrence compared with 0.8% of those with luminal A 
cancers (i.e. ER/PR-positive and low grade cancers, which are most frequently seen in older 
patients).33 This is consistent with data from Liu et al. which suggest that omission of 
radiation is an important consideration in those with luminal A cancers because of a 1.3% 
risk for in-breast recurrence with tamoxifen alone.34 The timing of ipsilateral breast events is 
also influenced tumor biology, with a shorter time-to-local-recurrence for those with triple 
negative disease vs. other tumors.35 However, the risk of a recurrence may be lower for such 
women who haven’t recurred within a decade of their cancer diagnosis compared to women 
with ER-positive tumors.
Other studies have reported much lower rates of recurrence than the EBCTCG meta-
analysis, with a risk of ipsilateral locoregional recurrence of up to 10%,10,36–39 and more 
recent studies have quoted even lower rates.40,41 These recent studies also demonstrate a 
protective effect of older age on risk of recurrence. For example, in a study of 1,434 women 
with stage I-II disease treated with BCS and radiation during 1997–2006 (median follow-up 
85 months), 2.1% of women experienced a locoregional recurrence by 5 years, and rates 
were lowest for those with luminal A cancers and for the oldest patients (0.4% of women 
aged 64–88 had local recurrences vs. 4.7% aged 23–46; hazard ratio [HR] for 
recurrence=0.97 for each increasing year of age, 95% CI=0.94–0.99).41 This is consistent 
with evidence from Cancer and Leukemia Group B Trial 9343, where 0.6% of women age 
≥70 receiving radiation and tamoxifen developed ipsilateral recurrences after a median 
follow-up of 12.6 years, and only 6% of those receiving tamoxifen alone developed an 
ipsilateral recurrence.42,43 Similarly, data from the PRIME II trial which examined BCS 
with or without radiation in patients aged ≥65 years receiving hormonal therapy 
demonstrated local recurrences of <5% in both groups at a median follow-up of 5 years and 
no differences in distant recurrences or survival.44
Certainly, these studies suggest that the vast majority of older patients with low risk cancers 
will have a risk of ipsilateral recurrence of much less than 10%, particularly for those 
receiving radiation and/or hormonal therapy. Further, for those receiving extended hormonal 
therapy such as those treated on MA.17R where the median age was 65.1 years at the time 
of randomization (4.5–6 years after starting aromatase inhibitor [AI] therapy; nearly 80% of 
women received tamoxifen prior to AI), <1% of women developed ipsilateral breast events 
at 6.3 years.45 Interestingly, approximately half of patients treated on study had node-
positive breast cancers with an anticipated higher locoregional recurrence risk over time.
Contralateral Risk of Breast Cancer in Breast Cancer Survivors
The risk for contralateral breast cancer (CBC) for older breast cancer survivors over time is 
even less defined than ipsilateral risk. In general and across age groups, the risk for CBC for 
those with a history of one cancer ranges from 2–11% over time, approximately 2–6 times 
the general population risk for developing a first cancer.46 In a review of relevant studies, the 
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incidence rate for CBC was reported to be 4–8 per 1000 person-years, with a lower risk with 
increasing age.46 A more recent, large study in Denmark of 85,863 women diagnosed with 
breast cancer during 1978–2009 with a median follow-up of 5.6 years (interquartile range 
2.3–10.9 years) reported similar findings, with 3.6% of women developing CBC.11 
Moreover, the incidence of CBC declined after 1997 in this study and others,47 likely as a 
result of improved systemic and hormonal therapy.11 The occurrence of CBC was 
significantly lower for older (vs. younger) Danish women, with a sharp decline in incidence 
after age 65 (incidence rate ratios [IRR] of CBC=0.52 for ages 70–74, 95% CI=0.44–0.62 
and IRR=0.68 for ages ≥75, 95% CI=0.58–0.80; both vs. ages 50–54); incidence rates were 
highest for women age <3511 and others have also shown a decrease in risk for CBC with 
increasing age.47 Of note, the development of CBC in the Danish registry study was 
independent of time since a patient’s first cancer across all ages, with steady rates over 10 
years of follow-up.11
Information can also be gained by examining outcomes of large adjuvant hormonal therapy 
trials such as the ‘Arimidex, Tamoxifen, Alone or in Combination’ (ATAC) trial where the 
median age at randomization was 64.48 At a median follow-up of 120 months (and a median 
age of 72), approximately 3% of patients taking hormonal therapy developed CBC.49 
Results from the ATAC cohort are likely generalizable to the majority of older patients seen 
in practice who have ER-positive tumors and who are taking hormonal therapy, with an 
associated risk reduction for both ipsilateral and contralateral events. These collective data 
suggest that older patients, and particularly those taking endocrine therapy, have a 3–5% 
chance of developing CBC over the course of 10 years after their initial diagnosis, which is 
similar to the general population risk of 1 in 27 (3.7%)6 for developing a first cancer during 
ages 70–80 (though it is important that risks for ipsilateral in-breast events in breast cancer 
survivors are also accounted for when determining overall risk). Further, for those on the 
MA.17R trial described above, the risk for CBC in 1,918 study participants was very low at 
a median follow-up of 6.3 years regardless of treatment assignment, with contralateral events 
occurring in 1.4% of women on extended letrozole and 3.2% for those on placebo.45,50
Tumor biology also plays a role in the risk of CBC for older breast cancer survivors. For 
women aged 70–74 at first diagnosis, those with an ER-positive first cancer have an 
incidence rate of 0.37 per 100/year) (95% CI=0.33–0.41), while those with an ER-negative 
first cancer have an incidence rate of 0.55 (per 100/year) (95% CI=0.47–0.73), likely due to 
the risk reduction provided by hormonal therapy.47
Benefits and Harms of Surveillance Mammography in Older Breast Cancer 
Survivors
Once treatments are optimized, the risk of developing in-breast events is quite low in older 
breast cancer survivors. Further, some of these in-breast events will be in-situ cancers only, 
where treatments have not shown to improve breast cancer mortality.51 Consequently, the 
low risk of localized recurrences combined with the increasing comorbidity (and hence 
competing causes of mortality) in this population call into question the benefit of 
surveillance mammography. This may be particularly relevant for those with an initial 
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diagnosis of in-situ disease, where the risk of death from breast cancer approximates that of 
the general population (3.3%).51 It is likely that surveillance mammography among women 
with primary in-situ disease may be of even lower benefit than that for women with invasive 
cancer.
Quantifying the benefits of surveillance testing without prospective data is very challenging. 
Studies have suggested ongoing benefit but are limited in interpretation because of the biases 
inherent to retrospective medical records or claims-based data, where survival benefits of 
screening may be significantly confounded by the fact that healthy, older breast cancer 
survivors are more likely to undergo surveillance mammography than less healthy ones and 
are thus more likely to survive longer. In a study of mammography and survival among 
1,846 breast cancer survivors age ≥65 with stage I-II breast cancer, each additional 
surveillance mammogram was associated with a 0.69 fold decrease in the odds of breast 
cancer mortality (95% CI=0.52–0.92).52 However, this study was likely substantially 
confounded by the excellent health of women undergoing surveillance imaging.52 A similar 
study also demonstrated mortality benefits of surveillance mammography with increasing 
age and found that the benefits of mammography were consistent even beyond the first five 
years after a diagnosis.53 Neither of these studies addressed the potential harms of screening. 
Recently, Massimino et al.54 published a single institution study assessing surveillance 
mammography in women aged ≥80 with a history of invasive/in-situ breast cancer. At a 
mean follow-up of 50 months, 429 women had undergone 1,466 mammograms that detected 
13 non-palpable cancers (0.9%), while 9 additional cancers were detected by physical exam. 
Although the study did not assess long-term outcomes, these findings raise questions about 
the value of surveillance mammography in older women.
The harms of surveillance mammography are poorly quantified for older patients. The main 
risks include over-diagnosis, false positive results, unnecessary biopsies, and the associated 
pain and anxiety,19–23,26,55 which may be heightened among women with a breast cancer 
history. Although studies have suggested that the false positive rate is lower in older vs. 
young women,54,56,57 the cumulative probability of having a false-positive mammogram 
over 10 years is 14–27% for those having biennial mammography and twice that for those 
undergoing annual mammography.26 Further, given the comorbidity present in many older 
patients and the fact that many will die of non-breast cancer causes,3–5 over-diagnosis and 
the ensuing overtreatment are even more significant than in younger patients.19–23
Can We Ever Stop Surveillance Mammography in Older Breast Cancer 
Survivors?
Given the lack of prospective and randomized data available, it is challenging to know which 
older patients might derive benefit from surveillance mammography. With increasing 
recognition of the role of functional rather than chronological age, it is difficult to place age 
cut-offs for recommendations that are meaningful for both healthy and frail patients. 
However, the available data for surveillance mammography in older women allow some 
conclusions to be drawn. First, increasing age is consistently associated with a lower risk of 
in-breast events, and this risk is further reduced by hormonal therapy and/or radiation. 
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Second, there is a consistent suggestion that rates of ipsilateral recurrences and contralateral 
breast events are low but persistent over time. Given this, the timing of mammography 
cessation should not be specifically dictated by the time from diagnosis. However, as 
patients age and the probability of dying from breast cancer decreases,3–5 increasing time 
from diagnosis will impact/lower the breast cancer mortality benefits of screening.
It is impossible to derive a one-size-fits-all surveillance approach across all older patients 
with varying comorbidity and functional status. Although it is ideal to prospectively study 
the impact of surveillance mammography for this population, it is unlikely that we will ever 
have large scale, prospective clinical trials that will optimally answer these questions for 
older breast cancer survivors. Despite these challenges, it may still be possible to develop 
some consensus on how to tailor recommendations.
A Starting Point?
The NCCN Older Adult Oncology Guidelines were recently updated to include 
recommendations about surveillance mammography in older breast cancer survivors, stating 
that risks and benefits should be discussed, decisions should be individualized, and that 
patients with a life expectancy of <5 years are unlikely to benefit from ongoing 
mammography28 (Table 1). Here, we aim to build upon these recommendations and suggest 
a more comprehensive framework to facilitate dialogue with patients. Although not 
specifically validated for breast cancer survivors, we suggest estimating life expectancy 
using standard life tables26,28 (Table 2) or newer tools that incorporate health status, such as 
ePrognosis,29 and we recommend the following surveillance approach and talking points 
(Tables 2 and 3). In recently diagnosed older patients, obtain a mammogram 6–12 months 
after local treatment to establish a baseline for future comparisons. From there, recognizing 
the slightly increased risk for new primary cancers and a potential clinical benefit of 
surveillance mammography in survivors beyond that seen in screening populations, we 
suggest that healthy 70–80 year-old breast cancer survivors have annual or biennial 
mammography, similar to the ACS and USPTSF general screening recommendations. 
Biennial mammography would aim to maintain the benefits of surveillance, while 
minimizing the potential harms of mammography and would allow patients to ease into a 
less rigorous surveillance program over time. Once patients reach age >80 (where average 
life expectancy is <10 years)58 or if patients have advanced comorbidity at any age with a 
life expectancy of <5 years,30,53 the benefit of surveillance imaging is likely minimal, and 
we recommend discussion regarding the risks and benefits of cessation of routine 
surveillance mammography. We fully recognize the limitations in applying this framework 
to all patients but suspect these recommendations could apply to most women. However, if a 
woman enjoys extraordinary health at age 80 and has a life expectancy >10 years and 
strongly wishes to continue mammography, we support an informed decision with a focus 
on functional rather than chronological age. Further, if a woman is perceived to be at higher 
risk for local or contralateral breast events because of a known genetic mutation or because 
of her own disease characteristics and/or treatment plan (e.g., positive margins), annual 
surveillance is reasonable to continue for longer than the average older patient until life 
expectancy is <5 years. Conversely, women who are too frail to receive adjuvant therapy 
should not continue mammographic surveillance. Finally, we value and recommend regular 
Freedman et al. Page 8













follow-up and physical exams, including clinical breast exams, regardless of decisions on 
mammography so that clinically meaningful disease can be detected and treated as 
appropriate.
In the end, even with the absence of optimal evidence to support decisions, a unified 
approach is needed regarding surveillance mammography in older women. The approach we 
propose incorporates extrapolation of existing data and the individualized needs and wishes 
for older breast cancer survivors. Discussions with breast cancer survivors about 
mammography should take into consideration not only the risks of developing new or locally 
recurrent breast cancer, but the competing medical conditions that are more likely to impact 
survival, similar to other treatment and screening decisions. Further, priorities in follow-up 
care should be addressed regularly with all patients, regardless of age (Table 3), with a focus 
on treating underlying comorbidities and promoting a healthy lifestyle. The limited benefits 
of mammography should be addressed openly with patients and the ‘knee jerk reflex’ for 
indefinite annual mammography should be reconsidered, especially as it often is linked with 
a false security that mammography will forever improve one’s longevity. In addition and 
perhaps most importantly, clinicians should reassure patients that stopping mammography 
does not reflect “giving up on them” as they age, but simply approaching their follow-up 
care in a thoughtful way that prioritizes benefits, risks, and concerns. If women understand 
the reasons for the recommendations, even those who are initially reluctant may agree with 
these recommendations over time. Finally, with the aging population and growing number of 
older breast cancer survivors in coming years,9,59 it remains an urgent research priority to 
prospectively examine ways to optimize surveillance strategies and decision-making in this 
population.12
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Table 1
Selected Mammographic Screening and Surveillance Guidelines for Older Women
Screening Guidelines for Older Women
Guideline Society Year of most 
recent guideline 
update
Current Screening Guidelines for the Older Patient (Average Risk)
United States Preventative Services 
Task Force (USPSTF)8,17
2016 Age 50–74: recommend biennial screening
Age ≥75: current evidence is insufficient to assess the balance of benefits and 
harms of screening
American Cancer Society (ACS)7,16,17 2015 Women 55 years and older should transition to biennial screening or have the 
opportunity to continue screening annually.
Women should continue screening mammography as long as their overall health 
is good and they have a life expectancy of 10 years of longer.
National Comprehensive Cancer 
Network (NCCN)25
2015 Age ≥40: Annual screening mammogram
“With the high incidence of breast cancer in the elderly population, the same 
screening guidelines used for women who are age 40 or older are 
recommended. Clinicians should always use judgment when applying screening 
guidelines.
Canadian Task Force60 2011 Age 50–74: Mammogram every 2–3 years
No guidelines for mammography at 75 and older
United Kingdom-National Health 
Service61
2015 Age 50–70: Mammogram every 3 years
Routine screening not offered for age >70
Swiss Medical Board62,63 2014 No new screening programs; phase out all existing programs
Surveillance Mammography Guidelines for Older Women with a Personal History of Breast Cancer
NCCN64 2015 Annual surveillance without age specific guidance
NCCN Senior Oncology Guidelines28 2016 “Decisions about mammograms for older breast cancer survivors should 
incorporate discussions with patients about their risk of developing recurrent or 
new breast cancer, the potential benefits of mammography in improving 
outcomes, the potential harms of mammography, and patients’ values and 
preferences…There likely is no benefit to regular mammograms for older 
women with a life expectancy of less than 5 years. In this group..harms likely 
outweigh any potential benefits.”
American Society of Clinical 
Oncology (ASCO) and ACS Breast 
Cancer Survivorship Care Guidelines27
2015 Annual mammography
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Table 2
Life expectancy for women by current age, adapted from Walter et al and Actuarial Life Tables (Social 
Security Administration)26,28,58








Additional estimates based on comorbidity can be made using calculators such as ePrognosis.29
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Table 3
Suggested approach for surveillance mammography and physical exams for older breast cancer survivors a
Age/Timing Recommendations/comment
Annually, any age Calculate/estimate life expectancy29 and discuss individualized pros and cons of 
mammographic surveillance
Every 6–12 months, all ages Continue physical exams, including clinical breast exams, to find clinically significant 
cancers
One-time, 6–12 months after completion of 
local therapy
All patients; establish new baseline
Age 70–80 Offer annual or biennial mammographic surveillance b
Age >80 Consider stopping routine mammographic surveillance unless in extraordinary health or 
unless patient felt to have higher-than-average risk for ipsilateral or contralateral breast events 
c
Any age + advanced comorbidity Stop routine mammographic surveillance
Life expectancy < 5 years Stop routine mammographic surveillance
Annually, as needed, any age Re-assess surveillance plan as appropriate
a
to be used as a framework for discussion with patients; this is not intended as a one-size-fits-all approach
b
Consider biennial exams in those felt to be at lower risk (i.e. small, lower-risk tumors, those on endocrine therapy)
c
e.g., known or suspected genetic mutation, history of positive margins, high risk for bilateral breast events per provider discretion
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Table 4






• Relatively little evidence is available to guide decisions about surveillance mammography in older 
women
• Most guidelines leave decisions about mammography up to patients and providers but start 
recommending against mammography if life expectancy is limited due to other medical conditions
• Physical exam, including clinical breast exam, remains important and should continue
Quantifying 
individualized risks for 
locally recurrent or new 
breast events
• Overall, the risk for locally recurrent or new breast cancers following breast conserving surgery 
for older patients is low (approximately <10% at 10 years after surgery) and is even lower for 
women who have received hormonal therapy or radiation
• The risk for breast cancer in the other breast in older patients is low (approximately ≤10% at 10 
years after diagnosis) and is even lower for women who have received hormonal therapy
• Risks are influenced by the cancer subtype, margin status, inherited pre-dispositions to cancer and 
should be included in decision-making
Potential benefits of 
screening and 
surveillance
• Mammograms are used to detect early-stage cancers and localized recurrences with a goal of 
lowering the risk of dying of breast cancer, but this benefit is less clear for older women
• Because cancer survivors may have a higher risk of breast cancer than women in the general 
population, they may benefit more; however, any mortality benefits of mammography decrease 
with increasing age
Potential harms of 
screening and 
surveillance
• Potential harms include false positive tests, unnecessary biopsies, over-diagnosis (finding cancers 
that would never become clinically significant in a patient’s lifetime), and lack of mortality 
benefit19–23,26,55
• Harms not well studied in the surveillance setting but extrapolated from screening literature
Life expectancy and 
patient/provider 
preferences
• One’s comorbidity, functional status, frailty, and life expectancy will impact how much a patient 
benefits from mammography
• Women with a shorter life expectancy will benefit less from mammography
• Life expectancy should be approximated when making decisions about mammography (Table 3)
Reassurance • Patients should be reassured that stopping mammography does not reflect “giving up on them” as 
they age, but simply approaching their follow-up care in a thoughtful way that prioritizes benefits, 
risks, and concerns
• Regular physical exams, including clinical breast exams, should continue
Decision-making • Patient and family preferences should be included in decisions
• Plan for surveillance mammography can be reassessed every 1–2 years as needed
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